JOHNSON & JOHNSON
Government Contracts & Awards
NORTH EAST SOUTH WEST HEALTHCARE SOLUTIONS, LLC: $16.5M Department of Homeland Security Contract
$16,465,998Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About
Things are going well for the pharmaceutical giant.
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). If approved, it would provide a new treatment for patients whose disease has progressed following platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Priority Review is grante
Johnson & Johnson (JNJ) Seeks $5.5 Billion Talc Lawsuit Settlement
Johnson & Johnson proposed a $5.5b settlement to resolve tens of thousands of ovarian cancer talc lawsuits. The offer aims to address a decade-long legal dispute involving the company’s talcum powder products. The settlement would require approval from a majority of claimants before it can move forward. For investors watching Johnson & Johnson (NYSE:JNJ), this legal development sits alongside a stock that closed at $265.53 and has recently shown strong momentum. The shares are up 3.9% over...
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
NEW BRUNSWICK, N.J., July 29, 2026--Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s oncology portfolio and advances its ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven can
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
NEW BRUNSWICK, N.J., July 29, 2026--Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease program and broader platform technology, with incentives to expand the application of Sail's in vivo CAR-T platform across additional therapeutic targets over time. John
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
But is that performance sustainable?
Freehand Raises $75M to Scale AI Teams Managing Supply Chain Spend for Fortune 500 Companies
Freehand's AI Agents autonomously manage supply-chain spend for Meta, Unilever, Johnson & Johnson, Dunkin', Pfizer and Cardinal Health. Freehand's AI Agents autonomously manage supply-chain spend for Meta, Unilever, Johnson & Johnson, Dunkin', Pfizer and Cardinal Health among others. Freehand builds autonomous AI agents that run supply-chain spend for the world's largest enterprises — taking on procurement, supplier management, invoice and payment operations across complex categories such as log
Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth
Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.
Freehand Raises $75M to Scale AI Teams Managing Supply Chain Spend for Fortune 500 Companies
Battery Ventures is co-leading the round alongside NewRoad Capital Partners, with participation from PSP Growth, Nexus Venture Partners and othersFreehand's AI Agents autonomously manage supply-chain spend for Meta, Unilever, Johnson & Johnson, Dunkin', Pfizer and Cardinal Health SAN FRANCISCO, July 29, 2026 (GLOBE NEWSWIRE) -- Freehand, whose AI agents manage supply-chain spend for Fortune 500 enterprises, today announced $75 million in funding co-led by Battery Ventures and NewRoad Capital Par
These 3 Companies Reported Record Results and Raised Guidance
Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks.
Congressional Trades in $JNJ
Insider Trades (Form 4)
Broadhurst Vanessa
Woods Eugene A.
Key People
Broadhurst Vanessa
EVP, Global Corp Affairs
Woods Eugene A
Director
Political Giving
$353,500 given to 56 candidates across 199 disclosed contributions (FEC Schedule A).
Scott H. Peters
Earl Leroy Carter
August Lee Pfluger
Gus M. Bilirakis
Thomas H. Kean
John Rutherford
Kevin Hern
Katherine M. Clark
Bradley S. Schneider
Diana Harshbarger
Suzan K. DelBene
Jake Auchincloss
Terri A. Sewell
Josh Gottheimer
Adrian Smith
Darin McKay LaHood
Darrell E. Issa
John Cornyn
Nanette Barragan
Shelley Moore Capito
+ 36 more recipients not shown.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro